820Triple Combination Treatment With Peginterferon Lambda-1a, Daclatasvir and Ribavirin for 12 Weeks in Patients Infected With HCV Genotype 1b
نویسندگان
چکیده
Daclatasvir and Ribavirin for 12 Weeks in Patients Infected With HCV Genotype 1b Maurizia Brunetto, MD; Khurram Rana; Gloria Taliani; Eric Lawitz; Christophe Hézode; Patrick Marcellin; Lawrence Serfaty; David Cohen; Subasree Srinivasan; Liver Unit University Hospital of Pisa, Pisa, Italy; BristolMyers Squibb, Wallingford, CT; Azienda Ospedaliera Universitaria, Policlinico Umberto I, Roma, Italy; Texas Liver Insititute, University of Texas Health Science Center, San Antonio, TX; CHU Henri Mondor, Service d’Hépato-Gastroentérologie, Créteil, France; Hôpital Beaujon, Clichy, France; St Antoine Hospital, Pierre and Marie Curie University, Paris, France
منابع مشابه
مقایسه پاسخ درمانی مداوم بیماران مبتلا به هپاتیت مزمن C با رژیم اینترفرون معمولی در مقابل پگیلیتد اینترفرون
Introduction: Based on data from recent trials, peginterferon and ribavirin combination therapy is the standard of care in treating patients with chronic HCV infection, but because of high costs, many patients may deprive from treatment. Methods: We conducted a clinical trial on HCV patients in Yazd in gastroenterology clinic. Thirty patients received conventional subcutaneous interferon alf...
متن کاملA randomized, controlled study of peginterferon lambda-1a/ribavirin ± daclatasvir for hepatitis C virus genotype 2 or 3
BACKGROUND AND PURPOSE Peginterferon Lambda was being developed as an alternative to alfa interferon for the treatment of chronic hepatitis C virus (HCV) infection. We compared peginterferon Lambda-1a plus ribavirin (Lambda/RBV) and Lambda/RBV plus daclatasvir (DCV; pangenotypic NS5A inhibitor) with peginterferon alfa-2a plus RBV (alfa/RBV) in treatment-naive patients with HCV genotype 2 or 3 i...
متن کاملDaclatasvir and asunaprevir plus peginterferon alfa and ribavirin in HCV genotype 1 or 4 non-responders.
BACKGROUND & AIMS Improved therapies for peginterferon/ribavirin null or partial responders are needed. This study evaluated daclatasvir (NS5A inhibitor) and asunaprevir (NS3 protease inhibitor) plus peginterferon alfa-2a and ribavirin in this patient population. METHODS This open-label, phase 3 study (HALLMARK-QUAD; NCT01573351) treated patients with chronic hepatitis C virus (HCV) genotype ...
متن کاملDaclatasvir plus sofosbuvir for HCV infection: an oral combination therapy with high antiviral efficacy.
BACKGROUND: All-oral combination therapy is desirable for patients with chronic hepatitis C virus (HCV) infection. We evaluated daclatasvir (an HCV NS5A replication complex inhibitor) plus sofosbuvir (a nucleotide analogue HCV NS5B polymerase inhibitor) in patients infected with HCV genotype 1, 2, or 3. METHODS: In this open-label study, we initially randomly assigned 44 previously untreated pa...
متن کاملAll-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study.
BACKGROUND An unmet need exists for interferon-free and ribavirin-free treatments for chronic hepatitis C virus (HCV) infection. In this study, we assessed all-oral therapy with daclatasvir (NS5A replication complex inhibitor) plus asunaprevir (NS3 protease inhibitor) in patients with genotype 1b infection, including those with high unmet needs or cirrhosis, or both. METHODS We did this phase...
متن کامل